Major depression: Selecting safe and effective treatment

American Family Physician

Volumn 55, Issue 5, 1997, Pages 1683-1694

  Bhatia, Subhash C ^a   Bhatia, Shashi K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DECONGESTIVE AGENT; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NARCOTIC AGENT; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VASOCONSTRICTOR AGENT; VENLAFAXINE;

AGITATION; ANTICHOLINERGIC EFFECT; CARDIOTOXICITY; DEPRESSION; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; MAINTENANCE THERAPY; ORTHOSTATIC HYPOTENSION; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DIAGNOSIS, DIFFERENTIAL; HUMANS;

EID: 0030960686     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19.
2. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Depression in primary care: detection, diagnosis, and treatment. Clinical Practice Guidelines no. 5. Rockville, Md.: Government Printing Office, 1993; AHCPR publication no. 93-0550.
3. Feldman E, Mayou R, Hawton K, Ardern M, Smith EB. Psychiatric disorder in medical in-patients. Q J Med 1987;63:405-12.
4. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992;267:1478-83.
5. Williams JW Jr, Kerber CA, Murlow CD, Medina A, Aguilar C. Depressive disorders in primary care: prevalence, functional disability, and identification. J Gen Intern Med 1995;10:7-12.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:320-27.
7. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18.
8. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. Am J Psychiatry 1993;150:1447-65.
9. Managed care's focus on psychiatric drugs alarms many doctors. Talk therapy is discouraged. The Wall Street Journal 1995 Dec 1;Sect A:1 and A:4.
10. Glass RM. Mental disorders. Quality of life and inequality of insurance coverage [Editorial]. JAMA 1995;274:1557.
11. Spitzer RL, Kroenke K, Linzer M, Hahn SR, Williams JB, de Gruy FV III, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA 1995;274:1511-7.
12. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
13. Anton RF Jr, Burch EA Jr. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990;147:1203-8.
14. Walker EA, Katon WJ, Jemelka RP, Roy-Byrne PP. Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study. Am J Med 1992:92(Suppl 1A):26S-30S.
15. Rosenthal NE. Diagnosis and treatment of seasonal affective disorder. JAMA 1993;270:2717-20.
16. Quitkin FM, Harrison W, Stewart JW, McGrath PJ, Tricamo E, Ocepek-Welikson K, et al. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design. Arch Gen Psychiatry 1991;48:319-23.
17. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150(Suppl):1-26.
18. Richelson E. Pharmacology of antidepressants -characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-81.
19. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994;114:559-65.
20. Richelson E. Synaptic effects of antidepressants. J Clin Psychopharmacol 1996;16(Suppl 2):1S-7S.
21. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:431-59.
22. Physicians' Desk Reference. 51st ed. Montvale, N.J.: Medical Economics, 1997.
23. Lacy C, Armstrong L, Ingram N, Lance L, eds. Drug information handbook. 3d ed. Hudson, Ohio: LexiComp, 1995:60-1415.
24. Hyman SE, Arana GW, Rosenbaum JF, eds. Handbook of psychiatric drug therapy. 3d ed. Boston: Little, Brown, 1995:78.
25. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993;269:2673-5.
26. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Depression in primary care: detection, diagnosis, and treatment. Quick reference guide for clinicians no. 5. Rockville, Md.: Government Printing Office, 1993; AHCPR publicaton no. 93-0552.
27. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression 1994;2:109-12.
28. Labatte LA, Pollack MH. Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report. Ann Clin Psychiatry 1994;6:13-5.
29. Arnott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry 1994;164:838-9.
30. Yager J. Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: case report. J Clin Psychiatry 1986;47:210-1.
31. Rush JA, Clayton P, Galle B, Baron D, Bernstein L Jr, Evans DL, et al. Length of antidepressant therapy: Consensus Conference statement March 3, 1995, Dallas, Tex. Little Falls, N.J.: Health Learning System, 1995:1-8.
32. Preskorn SH. What is the message in the alphabet soup of cytochrome P450 enzymes? J Prac Psychiatry Behavioral Health 1995;1:237-40.
33. Preskorn SH. Clinical pharmacology of selective serotonin reuptake inhibitors. Caddo, Ok.: Professional Communications, 1996:81.
34. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(Suppl 2):37S-50S.
35. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
36. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
37. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-73.